The estimated Net Worth of Vivek K Jayaraman is at least $3.57 Million dollars as of 12 March 2024. Mr. Jayaraman owns over 53,041 units of Cerus stock worth over $1,801,239 and over the last 8 years he sold CERS stock worth over $458,303. In addition, he makes $1,312,270 as Chief Operating Officer and Chief Commercial Officer at Cerus.
Sign up
Mr. Jayaraman CERS stock SEC Form 4 insiders trading
Vivek has made over 9 trades of the Cerus stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 53,041 units of CERS stock worth $107,143 on 12 March 2024.
The largest trade he's ever made was exercising 112,900 units of Cerus stock on 12 March 2022 worth over $231,445. On average, Vivek trades about 25,760 units every 79 days since 2017. As of 12 March 2024 he still owns at least 878,653 units of Cerus stock.
You can see the complete history of Mr. Jayaraman stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Vivek Jayaraman biography
Vivek K. Jayaraman serves as Chief Operating Officer, Chief Commercial Officer of the Company. He previously served as our Chief Commercial Officer since August 2016. From October 2009 to February 2016, Mr. Jayaraman served as Vice President, Sales and Marketing of TriVascular Technologies, Inc., or TriVascular, where he oversaw TriVascular’s commercial expansion as the company grew from a preclinical, venture-backed startup into a publicly traded, global medical device company. Mr. Jayaraman received his MBA from the Wharton School at the University of Pennsylvania and holds dual bachelor’s degrees from the University of Michigan.
What is the salary of Vivek Jayaraman?
As the Chief Operating Officer and Chief Commercial Officer of Cerus, the total compensation of Vivek Jayaraman at Cerus is $1,312,270. There are 1 executives at Cerus getting paid more, with William Greenman having the highest compensation of $3,270,180.
How old is Vivek Jayaraman?
Vivek Jayaraman is 45, he's been the Chief Operating Officer and Chief Commercial Officer of Cerus since 2020. There are 13 older and no younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
What's Vivek Jayaraman's mailing address?
Vivek's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Insiders trading at Cerus
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash, and Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
What does Cerus do?
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
What does Cerus's logo look like?
Complete history of Mr. Jayaraman stock trades at Cerus
Cerus executives and stock owners
Cerus executives and other stock owners filed with the SEC include:
-
William Greenman,
President, Chief Executive Officer, Director -
Vivek Jayaraman,
Chief Operating Officer, Chief Commercial Officer -
Laurence Corash,
Chief Scientific Officer -
Richard Benjamin,
Chief Medical Officer -
Kevin Green,
Chief Financial Officer, Vice President - Finance -
Carol Moore,
Senior Vice President - Regulatory Affairs, Quality and Clinical -
Chrystal Menard,
Chief Legal Officer and General Counsel -
Jami Nachtsheim,
Independent Director -
Daniel Swisher,
Independent Chairman of the Board -
Timothy Anderson,
Independent Director -
Frank Witney,
Independent Director -
Gail Schulze,
Independent Director -
Eric Bjerkholt,
Independent Director -
Timothy Moore,
Independent Director -
Tim Lee,
Investor Relations Director -
William J Dawson,
Chief Financial Officer -
Caspar Jan Hogeboom,
Managing Director Cerus Europe -
Bruce C Cozadd,
Director -
David N Cook,
Vice President, R & D -
Chrystal Jensen,
Chief Legal Officer -
Stephen T Isaacs,
Chief Executive Officer -
Gregory W Schafer,
Chief Financial Officer -
International Inc & Subsidi...,
10% owner -
C Raymond Jr Larkin,
Director -
Bj Cassin,
Director -
Howard G Ervin,
Vice President, Legal Affairs -
Claes Glassell,
Executive Officer and Director -
William R Rohn,
Director -
Dean A. Gregory,
-
Ann Lucena,
Director -
Hua Shan,
Director